TH Open-Editor's Highlights of 2024.
作者信息
Koenen Rory R
机构信息
Department of Biochemistry, CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands.
出版信息
TH Open. 2025 Jan 27;9:a25134445. doi: 10.1055/a-2513-4445. eCollection 2025.
Abstract
摘要
相似文献
1
TH Open-Editor's Highlights of 2024.《2024年TH开放编辑精选》
TH Open. 2025 Jan 27;9:a25134445. doi: 10.1055/a-2513-4445. eCollection 2025.
2
From the Editor's Desk, Editor's Highlights, Letters to the Editor.来自编辑台、编辑要点、读者来信。
Toxicol Sci. 2016 Aug;152(2):257-61. doi: 10.1093/toxsci/kfw113.
3
From the Editor's Desk, Editor's Highlights, Letters to the Editor.来自编辑台、编辑要点、读者来信。
Toxicol Sci. 2016 Dec;154(2):197-199. doi: 10.1093/toxsci/kfw217.
4
From the Editor's Desk, Editor's Highlights, Letters to the Editor.来自编辑台、编辑要点、读者来信。
Toxicol Sci. 2016 Nov;154(1):1-4. doi: 10.1093/toxsci/kfw206.
5
[Carrying on the past heritage and opening up the new journey: chief editor's celebrating words for the 50 anniversary of the Chinese Journal of Cardiology].[传承既往，开启新程：主编为《中华心血管病杂志》创刊50周年的贺词]
Zhonghua Xin Xue Guan Bing Za Zhi. 2023 Apr 24;51(4):333-334. doi: 10.3760/cma.j.cn112148-20230209-00078.
6
Editor's choice: Tackling infectious diseases, NCDs and sexual reproductive health issues as we enter our 24 year of remarkable growth.编辑推荐：在我们迎来显著增长的第24个年头之际，应对传染病、非传染性疾病和性与生殖健康问题。
Afr Health Sci. 2024 Mar;24(1):i-iii. doi: 10.4314/ahs.v24i1.1.
7
An Editor's exit. Editor's-in-Chief of 21 years reflections.一位主编的离任。21年主编生涯的反思。
J Refract Surg. 2010 Oct;26(10):698-702. doi: 10.3928/1081597X-20100924-01.
8
Editor's highlights.编辑推荐。
Eur J Obstet Gynecol Reprod Biol. 2010 May 27. doi: 10.1016/j.ejogrb.2010.05.002.
9
Editor's choice: recent research highlights from the International Journal of Nanomedicine.编辑推荐：《国际纳米医学杂志》近期研究亮点
Int J Nanomedicine. 2017 Jun 19;12:4505-4508. doi: 10.2147/IJN.S140083. eCollection 2017.
10
Write a scientific paper (WASP): Editor's perspective of submissions and dealing with editors.撰写科学论文（WASP）：编辑对投稿及与编辑打交道的看法。
Early Hum Dev. 2019 Feb;129:93-95. doi: 10.1016/j.earlhumdev.2018.12.007. Epub 2018 Dec 19.
本文引用的文献
1
Management of Urgent Bleeding in Patients with Hemophilia A: Focus on the Use of Emicizumab.A型血友病患者紧急出血的管理：聚焦于艾美赛珠单抗的使用。
TH Open. 2024 Apr 17;8(2):e194-e201. doi: 10.1055/s-0044-1785525. eCollection 2024 Apr.
2
Disease Burden, Clinical Outcomes, and Quality of Life in People with Hemophilia A without Inhibitors in Europe: Analyses from CHESS II/CHESS PAEDs.欧洲无抑制物的甲型血友病患者的疾病负担、临床结局及生活质量：来自CHESS II/CHESS PAEDs的分析
TH Open. 2024 Apr 15;8(2):e181-e193. doi: 10.1055/s-0044-1785524. eCollection 2024 Apr.
3
Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B.重组凝血因子IX与白蛋白连接融合蛋白（rIX-FP）在既往未治疗的B型血友病患者中的安全性和有效性
TH Open. 2024 Mar 26;8(1):e155-e163. doi: 10.1055/s-0044-1781466. eCollection 2024 Jan.
4
Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors.来自STASEY研究的手术经验：emicizumab预防A型血友病伴凝血因子VIII抑制剂患者的情况
TH Open. 2024 Jan 12;8(1):e42-e54. doi: 10.1055/s-0043-1777766. eCollection 2024 Jan.
5
Anticoagulation-Associated Bleeding in Patients Screened for Atrial Fibrillation versus Usual Care-A Post Hoc Analysis from the LOOP Study.心房颤动筛查患者与常规治疗相比的抗凝相关出血——来自LOOP研究的事后分析
TH Open. 2024 Jan 8;8(1):e19-e30. doi: 10.1055/a-2202-4296. eCollection 2024 Jan.
Zotero 插件